Cell_Biology experiment designed to assess clinical efficacy targeting N/A in human. Primary outcome: Early disease phase characterized by remyelination response from oligodendrocyte precursor cells.
Description
No description available
TARGET GENE
N/A
MODEL SYSTEM
human
ESTIMATED COST
$0
TIMELINE
0 months
PATHWAY
myelination
SOURCE
pmid_39402379
PRIMARY OUTCOME
Early disease phase characterized by remyelination response from oligodendrocyte precursor cells.